The Trump administration unveiled a federal initiative to accelerate research into psychedelic treatments for serious mental illness, with a particular focus on helping veterans battling post-traumatic stress disorder. HHS Secretary Robert F. Kennedy Jr. announced the multi-million dollar commitment alongside leaders from the FDA, Veterans Affairs, and the Advanced Research Projects Agency for Health (ARPA-H).
The centerpiece of the announcement involves a $4.9 million investment through ARPA-H to advance ibogaine as a potential PTSD treatment. Ibogaine, a naturally occurring alkaloid, has shown promise in clinical settings but remains largely unstudied within the U.S. medical system. The funding will support the regulatory, manufacturing, and scientific work necessary to prepare for future American clinical trials.
Mark Cuban’s company will lead efforts to develop the regulatory and manufacturing processes needed to produce ibogaine hydrochloride domestically. The partnership emphasizes transparency and affordability, with all data to be open-sourced and pricing structured to match generic drug costs.
“We’re going to open source every aspect of this system so that we know that we’re getting the best prices that we could possibly get,” Kennedy explained.
A Texas-based company operating in Mexico will contribute years of international clinical data from more than 3,000 patients who have received approximately 6,000 doses of ibogaine. This existing evidence will help accelerate the domestic trial process without compromising safety standards. The research will assess clinical data, safety protocols, dosing procedures, and the duration of any potential benefits.
The National Institute of Mental Health is simultaneously committing $20 million to establish a research network examining rapid-acting psychotropic [ ], including ketamine, esketamine, and psilocybin. The funding will support studies across five years, with award recipients expected to be announced in summer 2027.
Kennedy emphasized that these announcements fund development groundwork only and do not authorize clinical trials or constitute FDA approval.
“These awards fund development groundwork. They do not fund patient treatment or human subject research or authorize clinical trials or constitute an FDA approval. We must maintain those distinctions as this research proceeds,” he stated.
The research will require participants to meet accelerated milestones to receive continued funding, with all teams subject to strict safety monitoring and ethics oversight.
The FDA has opened a public comment period through November 20th, inviting researchers, clinicians, veterans, and families to contribute input on trial design, dosing, participant eligibility, and safety protocols. This collaborative approach marks an unusual shift toward transparency in pharmaceutical research, where companies typically keep trial data proprietary.
VA leadership emphasized veteran safety as the top priority. “For veterans living with PTSD, we owe them both urgency and the best science we can produce,” said Andrew Gratison, representing the Department of Veterans Affairs.
The initiative builds on President Trump’s April executive order directing federal health agencies to accelerate research into potential treatments for serious mental illness. Veterans in crisis can reach the Veterans Crisis Hotline at 988 and press 1 for support.
Joe Rogan has been a prominent advocate for psychedelic research, particularly ibogaine’s potential to help veterans suffering from PTSD and addiction. During an April 2026 White House event, Rogan joined President Donald Trump as he signed an executive order accelerating research into psychedelic therapies.
